Intuitive Surgical, Inc (ISRG) Fair Value & Analysis
Healthcare · US · Market cap $148B
Intuitive Surgical, Inc
ISRG · US
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 8 days ago
Fair value updated Jun 24, 2026 — revised from $182.39 to $151.86 (−16.7%) since Jun 23, 2026. Share price +5.9% over the past month.
Price vs Fair Value (12 months)
12‑month range $376.37 – $561.08 · fair‑value band $109.72 – $240.03 · the $403.18 price screens above the $151.86 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Intuitive Surgical, Inc (ISRG) currently trades at $403.18, while our model-based Fair Value estimate is $151.86 — implying the stock looks roughly 62.3% overvalued today. We read business quality at 63/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Intuitive Surgical, Inc generated revenue of $10.6B at a net margin of 28.2%. Revenue grew 23.0% year over year. It earns a return on equity of 17.2%. The balance sheet holds a net cash position of $3.1B. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Intuitive Surgical, Inc reported revenue of $10.1B in FY2025 versus $5.7B in FY2021, a compound +15.2%/yr. Reported net income was $2.9B in FY2025, compounding +13.8%/yr from FY2021.
Is ISRG fairly valued? → Check now
Recent news
- Can ISRG's 'Quintuple Aim' Strategy Continue to Justify Premium Pricing?
- Veeva Acquires Copli & Launches Falcon MLR for Faster Content Reviews
- Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
- SA Asks: What's the most attractive robotics stock right now?
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| EssilorLuxottica Société anonyme ESLOF | $192.00 | $126.51 | -34% |
| HOYA Corporation HOCPY | $178.46 | $103.27 | -42% |
| Medline Inc MDLN | $36.54 | $30.66 | -16% |
| Becton, Dickinson and Company BDX | $147.79 | $124.26 | -16% |
| Alcon Inc ALC | $66.11 | $36.99 | -44% |
| ResMed Inc RSMDF | $16.99 | $20.87 | +23% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Intuitive Surgical, Inc (ISRG) undervalued?
What is the fair value of ISRG?
What is the quality score of ISRG?
What is the revenue of Intuitive Surgical, Inc (ISRG)?
What is the net profit margin of ISRG?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.